DUBLIN, April 30, 2020 /PRNewswire/ -- The "SRP-9001 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

The report provides comprehensive insights about an investigational product for Duchene muscular dystrophy (DMD) in 7 Major Markets.

A detailed picture of the SRP-9001 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

SRP-9001 is being developed by Sarepta Therapeutics which is currently in Phase II clinical development for the treatment of Duchenne muscular dystrophy. It is designed to deliver the micro-dystrophin-encoding gene directly to the muscle tissue for the targeted production of the micro-dystrophin protein. Roche has acquired exclusive commercial rights outside the United States to Sarepta Therapeutics' lead gene therapy pipeline candidate SRP-9001 for Duchenne muscular dystrophy (DMD).

The report provides insights into:

Report Highlights

Key Questions Answered

Key Topics Covered

1. Drug Overview1.1. Product Detail1.2. Mechanism of Action1.3. Dosage and Administration1.4. Research and Development Activity1.4.1. Clinical Development1.4.2. Safety and Efficacy1.5. Other Development Activities

2. Market Assessment2.1. 7MM Market Analysis2.2. The United States Market2.3. Germany Market2.4. France Market2.5. Italy Market2.6. Spain Market2.7. United Kingdom Market2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

List of TablesTable 1 SRP-9001, DescriptionTable 2 SRP-9001, Clinical Trial DescriptionTable 3 SRP-9001, 7MM Market Size from 2020 to 2030 (in Million USD)Table 4 Market CompetitorsTable 5 Other Emerging Therapies

List of FiguresFigure 1 The Development Timeline of SRP-9001 Figure 2 Patent Details, SRP-9001 Figure 3 SRP-9001, 7MM Market Size from 2020 to 2030 (in Million USD)Figure 4 SRP-9001, US Market Size from 2020 to 2030 (in Millions USD)Figure 5 SRP-9001, EU5 Market Size from 2020 to 2030 (in Millions USD)Figure 6 SRP-9001, Japan Market Size from 2020 to 2030 (in Millions USD)

For more information about this report visit https://www.researchandmarkets.com/r/5p03nc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/srp-9001-sarepta-therapeutics-emerging-insights-and-market-forecast-to-2030-301050426.html

SOURCE Research and Markets

More here:
SRP-9001 [Sarepta Therapeutics] Emerging Insights and Market Forecast to 2030 - P&T Community

Comments are closed.